Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Biologic therapy. Immunotherapy. The Methodist Hospital Research Institute, Houston, Texas, United States

Survival: ?
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Proleukin
Country: United States
City/State/Province: Houston, Texas
Hospital: The Methodist Hospital Research Institute
Journal: Link
Date: 2/2006

Patients: The phase I/II study involved a total of 52 patients with metastatic renal cell carcinoma.

Treatment: The treatment consisted of a combination of biological therapy (thalidomide) and immunotherapy (interleukin-2).

Toxicity: For phase I, toxicities included: grade 3/4 fluid retention and grade 3 constipation. For phase II, toxicities included: grade 4 fatigue and skin toxicities.

Results: Overall median survival was not reported. Survival for individual patients ranged from a low of 1 month (1 patient) to a high of over 45 months (1 patient).

Support: One of the authors has received a grant from Celegene Corporation. Celgene manufactures and/or markets thalidomide.

Correspondence: Robert J. Amato, D.O.

E-mail to a Friend Email Physician More Information